Association between changes in CMS reimbursement policy and drug labels for erythrocyte-stimulating agents with outcomes for older patients undergoing hemodialysis covered by fee-for-service medicare

Cunlin Wang; Robert Kane; Mark Levenson; Jeffrey Kelman; Michael Wernecke; Joo Yeon Lee; Steven Kozlowski; Carmen Dekmezian; Zhiwei Zhang; Aliza Thompson; Kimberly Smith; Yu Te Wu; Yuqin Wei; Yoganand Chillarige; Qin Ryan; Chris Worrall; Thomas E. MaCurdy; David J. Graham

doi:10.1001/jamainternmed.2016.6520

Association between changes in CMS reimbursement policy and drug labels for erythrocyte-stimulating agents with outcomes for older patients undergoing hemodialysis covered by fee-for-service medicare

Cunlin Wang, Robert Kane, Mark Levenson, Jeffrey Kelman, Michael Wernecke, Joo Yeon Lee, Steven Kozlowski, Carmen Dekmezian, Zhiwei Zhang, Aliza Thompson, Kimberly Smith, Yu Te Wu, Yuqin Wei, Yoganand Chillarige, Qin Ryan, Chris Worrall, Thomas E. MaCurdy, David J. Graham

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1818-1825
Number of pages	8
Journal	JAMA Internal Medicine
Volume	176
Issue number	12
DOIs	https://doi.org/10.1001/jamainternmed.2016.6520
State	Published - Dec 1 2016
Externally published	Yes

ASJC Scopus Subject Areas

Internal Medicine

Access to Document

10.1001/jamainternmed.2016.6520

OpenUrl availability

Full text

Cite this

Wang, C., Kane, R., Levenson, M., Kelman, J., Wernecke, M., Lee, J. Y., Kozlowski, S., Dekmezian, C., Zhang, Z., Thompson, A., Smith, K., Wu, Y. T., Wei, Y., Chillarige, Y., Ryan, Q., Worrall, C., MaCurdy, T. E., & Graham, D. J. (2016). Association between changes in CMS reimbursement policy and drug labels for erythrocyte-stimulating agents with outcomes for older patients undergoing hemodialysis covered by fee-for-service medicare. JAMA Internal Medicine, 176(12), 1818-1825. https://doi.org/10.1001/jamainternmed.2016.6520

Association between changes in CMS reimbursement policy and drug labels for erythrocyte-stimulating agents with outcomes for older patients undergoing hemodialysis covered by fee-for-service medicare. / Wang, Cunlin; Kane, Robert; Levenson, Mark et al.
In: JAMA Internal Medicine, Vol. 176, No. 12, 01.12.2016, p. 1818-1825.

Research output: Contribution to journal › Article › peer-review

Wang, C, Kane, R, Levenson, M, Kelman, J, Wernecke, M, Lee, JY, Kozlowski, S, Dekmezian, C, Zhang, Z, Thompson, A, Smith, K, Wu, YT, Wei, Y, Chillarige, Y, Ryan, Q, Worrall, C, MaCurdy, TE & Graham, DJ 2016, 'Association between changes in CMS reimbursement policy and drug labels for erythrocyte-stimulating agents with outcomes for older patients undergoing hemodialysis covered by fee-for-service medicare', JAMA Internal Medicine, vol. 176, no. 12, pp. 1818-1825. https://doi.org/10.1001/jamainternmed.2016.6520

@article{88e504fc0a1c468a8ae971f26182fc10,

title = "Association between changes in CMS reimbursement policy and drug labels for erythrocyte-stimulating agents with outcomes for older patients undergoing hemodialysis covered by fee-for-service medicare",

author = "Cunlin Wang and Robert Kane and Mark Levenson and Jeffrey Kelman and Michael Wernecke and Lee, {Joo Yeon} and Steven Kozlowski and Carmen Dekmezian and Zhiwei Zhang and Aliza Thompson and Kimberly Smith and Wu, {Yu Te} and Yuqin Wei and Yoganand Chillarige and Qin Ryan and Chris Worrall and MaCurdy, {Thomas E.} and Graham, {David J.}",

year = "2016",

month = dec,

day = "1",

doi = "10.1001/jamainternmed.2016.6520",

language = "English",

volume = "176",

pages = "1818--1825",

journal = "JAMA Internal Medicine",

issn = "2168-6106",

number = "12",

}

TY - JOUR

T1 - Association between changes in CMS reimbursement policy and drug labels for erythrocyte-stimulating agents with outcomes for older patients undergoing hemodialysis covered by fee-for-service medicare

AU - Wang, Cunlin

AU - Kane, Robert

AU - Levenson, Mark

AU - Kelman, Jeffrey

AU - Wernecke, Michael

AU - Lee, Joo Yeon

AU - Kozlowski, Steven

AU - Dekmezian, Carmen

AU - Zhang, Zhiwei

AU - Thompson, Aliza

AU - Smith, Kimberly

AU - Wu, Yu Te

AU - Wei, Yuqin

AU - Chillarige, Yoganand

AU - Ryan, Qin

AU - Worrall, Chris

AU - MaCurdy, Thomas E.

AU - Graham, David J.

PY - 2016/12/1

Y1 - 2016/12/1

UR - http://www.scopus.com/inward/record.url?scp=85011277763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011277763&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2016.6520

DO - 10.1001/jamainternmed.2016.6520

M3 - Article

C2 - 27775769

AN - SCOPUS:85011277763

SN - 2168-6106

VL - 176

SP - 1818

EP - 1825

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

IS - 12

ER -

Association between changes in CMS reimbursement policy and drug labels for erythrocyte-stimulating agents with outcomes for older patients undergoing hemodialysis covered by fee-for-service medicare

ASJC Scopus Subject Areas

Access to Document

OpenUrl availability

Other files and links

Cite this